Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Kenvue Inc. (KVUE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: KVUE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $24.69
1 Year Target Price $24.69
| 3 | Strong Buy |
| 2 | Buy |
| 14 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -23.98% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 40.41B USD | Price to earnings Ratio 37.59 | 1Y Target Price 24.69 |
Price to earnings Ratio 37.59 | 1Y Target Price 24.69 | ||
Volume (30-day avg) 19 | Beta 0.93 | 52 Weeks Range 17.03 - 24.95 | Updated Date 07/5/2025 |
52 Weeks Range 17.03 - 24.95 | Updated Date 07/5/2025 | ||
Dividends yield (FY) 3.92% | Basic EPS (TTM) 0.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 6.9% | Operating Margin (TTM) 16.71% |
Management Effectiveness
Return on Assets (TTM) 6.77% | Return on Equity (TTM) 10.22% |
Valuation
Trailing PE 37.59 | Forward PE 18.42 | Enterprise Value 48210104194 | Price to Sales(TTM) 2.64 |
Enterprise Value 48210104194 | Price to Sales(TTM) 2.64 | ||
Enterprise Value to Revenue 3.15 | Enterprise Value to EBITDA 19.41 | Shares Outstanding 1919910016 | Shares Floating 1916991675 |
Shares Outstanding 1919910016 | Shares Floating 1916991675 | ||
Percent Insiders 0.04 | Percent Institutions 101.17 |
Upturn AI SWOT
Kenvue Inc.
Company Overview
History and Background
Kenvue Inc. was spun off from Johnson & Johnson in May 2023, becoming an independent publicly traded company. It focuses on consumer health products, building on J&J's established brands. The spin-off aimed to allow J&J to focus on pharmaceuticals and medical devices, while Kenvue could concentrate on its consumer health portfolio.
Core Business Areas
- Self Care: This segment includes pain relief, cough/cold, allergy, and digestive health products. Notable brands include Tylenol, Motrin, Benadryl, and Imodium.
- Skin Health and Beauty: This segment comprises skincare, sun care, and personal care brands. Key brands are Neutrogena, Aveeno, and Clean & Clear.
- Essential Health: This segment includes oral care, wound care, and other essential health products. Leading brands are Listerine, Band-Aid, and Neosporin.
Leadership and Structure
Thibaut Mongon serves as Chief Executive Officer. The company has a typical corporate structure with various executive leadership positions overseeing different functional areas and business segments.
Top Products and Market Share
Key Offerings
- Tylenol: A leading pain reliever and fever reducer. Competitors: Advil (GSK), Aleve (Bayer), generic acetaminophen. It is the leader in pain relief category.
- Neutrogena: A skincare brand offering a wide range of products. Competitors: L'Oru00e9al, Unilever, P&G. It is very well known for their acne treatment.
- Listerine: An oral care brand focused on mouthwash. Competitors: Crest (P&G), Colgate-Palmolive. It is among the leaders in mouthwash.
- Band-Aid: A brand of adhesive bandages. Competitors: Curad (Medline), generic bandages. It has a high level of brand recognition.
- Aveeno: Skincare products focused on natural ingredients, including moisturizers. Competitors: Eucerin (Beiersdorf), Cetaphil (Galderma).
Market Dynamics
Industry Overview
The consumer health industry is characterized by steady growth driven by an aging population, increased health awareness, and expanding access to healthcare. The industry is competitive, with large multinational corporations and smaller niche players.
Positioning
Kenvue holds a strong position in the consumer health industry due to its portfolio of established and trusted brands. Its competitive advantages include brand recognition, distribution networks, and innovation capabilities.
Total Addressable Market (TAM)
The global consumer health market is estimated to be in hundreds of billions of dollars. Kenvue is well positioned to capture a significant portion of this market due to its diverse portfolio and global presence.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Diversified product portfolio
- Global distribution network
- Innovation capabilities
- High Profit Margins on many products
Weaknesses
- High debt levels from the spin-off
- Reliance on a limited number of key brands
- Potential for generic competition
- Supply Chain Vulnerabilities
Opportunities
- Expanding into new markets and product categories
- Acquiring complementary brands
- Increasing e-commerce sales
- Leveraging data analytics to personalize products and services
Threats
- Intense competition
- Changing consumer preferences
- Regulatory changes
- Economic downturns
- Supply Chain disruptions
Competitors and Market Share
Key Competitors
- PG
- UN
- BAYRY
Competitive Landscape
Kenvue benefits from strong brands but faces intense competition from larger, diversified consumer goods companies. Kenvue aims to compete through innovation, targeted marketing, and efficient operations.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is based on pre-spin-off performance within Johnson & Johnson. Organic growth rate for FY 2023 was 3.8%.
Future Projections: Analysts project continued growth driven by expansion into new markets, product innovation, and acquisitions.
Recent Initiatives: Recent initiatives include focusing on e-commerce, developing new products, and optimizing the supply chain.
Summary
Kenvue is a strong company with a portfolio of well-known brands, but it also faces challenges related to its high debt levels. The company is focused on driving growth through innovation and expansion into new markets. Investors should monitor the company's progress in reducing debt and executing its growth strategy. Kenvue is an excellent consumer brand with growth potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Kenvue Inc. SEC Filings, MarketWatch, Company Investor Relations
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kenvue Inc.
Exchange NYSE | Headquaters Summit, NJ, United States | ||
IPO Launch date 2023-05-04 | CEO & Director Mr. Thibaut Mongon | ||
Sector Consumer Defensive | Industry Household & Personal Products | Full time employees 22000 | Website https://www.kenvue.com |
Full time employees 22000 | Website https://www.kenvue.com | ||
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.